"Designing Growth Strategies is in our DNA"

Pelvic Inflammatory Disease (PID) Treatment Market Size, Share and Global Trend By Drug Class (Quinolones, Tetracycline, Beta-lactam, Nitroimidazoles), By Type (Subacute Pelvic Inflammatory Disease, Chronic Pelvic Inflammatory Disease,Others), By Route of Administration (Oral, Intravenous, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Geography Forecast till 2021-2028

Region : Global | Report ID: FBI100204 | Status : Ongoing

 

KEY MARKET INSIGHTS

Pelvic Inflammatory Disease (PID) is a disease which is essentially the infection of the female reproductive organs and is generally caused due to the spread of the bacteria from the vagina and the cervix. In 75% to 90% of the incidences, the disease is caused by Chlamydia trachomatis or Neisseria gonorrhoeae and in many of the cases, the presence of multiple bacteria is found. According to the U.S. Department of Health and Human Services, the disease is common and affects more than 1 million individuals annually in the U.S. The primary course of treatment for the Pelvic Inflammatory Disease (PID) is through the administration of antibiotics and in some rarer cases with severe complications, the physicians may suggest surgery.

Most of the treatment is conducted through the intravenous/ parenteral and the oral or intramuscular route, with a variety of antibiotics equipped with treating various bacterial infections. Since most of the treatment is undertaken by antibiotics which are utilized for the treatment of other diseases too, a number of key pharmaceutical market leaders are present. A number of clinical trials are being undertaken for the treatment of pelvic inflammatory disease (PID), which includes antibiotics such as ceftriaxone, doxycycline, and metronidazole. Bayer AG has initiated a clinical trial in 2018 of a new molecular entity (BAY 1834845) for the treatment of Pelvic Inflammatory Disease (PID). 

To gain extensive insights into the market, Request for Customization

Pelvic Inflammatory Disease (PID) is a common disease among the females, with an estimated 1 million new diagnoses every year in the U.S. Thus, the number of individuals suffering from this disorder is expected to rise due to increasing global population coupled with increasing awareness about the disease in the emerging markets. These have led to many key market players such as Bayer AG to focus on the research & development of new treatment drugs for the disease or direct focus towards increasing the efficiency of the existing and approved drugs. 

The factor that is expected to inhibit the growth of the market is the stringent regulatory scenario and the associated regulatory hurdles that the companies have to undergo before receiving the regulatory approval. This stringent and convoluted process may deter many of the applicants undergoing the product development process for the marketing and commercialization approvals for their products. Some of the associated side effects of the drugs may also deter the growth of the market.

 Key Players Covered 

Some of the major companies that are present in the global pelvic inflammatory disease (PID) treatment market are F. Hoffmann-La Roche, Pfizer Inc., Lupin, Cambrex Corporation, Cipla Inc., Bayer AG, and DAIICHI SANKYO COMPANY, LIMITED. and other players. 

 SEGMENTATION

 

 SEGMENTATION

 DETAILS

By Drug Class

·      Quinolones

·      Tetracycline

·      Beta-lactam

·      Nitroimidazoles

·      Others

By Type

·      Subacute Pelvic Inflammatory Disease

·      Chronic Pelvic Inflammatory Disease

·      Sexually Transmitted Pelvic Inflammatory Disease

·      Others

By Route of Administration

·      Oral

·      Intravenous

·      Topical

·      Others

By Distribution Channel

·      Hospital Pharmacies

·      Retail Pharmacies

·      Online Pharmacies

·      Others

By Geography

·      North America (USA and Canada)

·      Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

·      Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

·      Latin America (Brazil, Mexico and Rest of Latin America)

·      Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

                       

At present, subacute pelvic inflammatory disease (PID) accounts for the largest proportion of the market by type and by geography, North America has the highest share of the pelvic inflammatory disease (PID) due to the high rate of occurrence of the disease, combined with the access to advanced treatment options and increasing awareness of the disease due to increasing demand for preventive medical care. 

Key Insights 

  • Prevalence of pelvic inflammatory disease (PID) by key countries
  • Advancements in the research & development of treatment options
  • Overview of advances in novel therapeutics
  • New product launches  

Regional Analysis 

The global pelvic inflammatory disease (PID) treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America followed by Europe are the two largest markets for pelvic inflammatory disease (PID) treatment at present and they are expected to account for a large proportion of the market in the forecast period as well. North America has a high rate of occurrence of the disease and this has led to a greater demand for the treatment options for the disease. In January 2019, the Food and Drug Administration (FDA) permitted the marketing of the first test to aid in the diagnosis of pelvic inflammatory disorder (PID). In the Asia Pacific region, Japan is expected to provide the largest market opportunity, with approximately 468,136 individuals out of its 127 million population, having already suffered from this disease or currently suffering from. 

Key Industry Developments

  • In January 2019, the Food and Drug Administration (FDA) for the first time gave the approval for the marketing of the first ever test to be utilized for the diagnosis of pelvic inflammatory disease (PID) called the Aptima Mycoplasma genitalium Assay.
  • Bayer AG is undertaking the clinical trial of a new molecular entity to be utilised in the treatment of the pelvic inflammatory disease (PID) called BAY1834845, which is currently in Phase 1 of the clinical trial process, as of December 2018.
  • A Chinese pharmaceutical company called the Jiangsu Hansoh Pharmaceutical Co., Ltd. is undertaking clinical trials to test for the safety and efficacy of morinidazole in the women diagnosed with pelvic inflammatory disease (PID) and is currently in Phase 4 of the clinical trials, as of January 2018.

Pelvic Inflammatory Disease (PID) Treatment Market Size, Share and Global Industry Trend Forecast till 2026
  • Ongoing
  • 2020
  • 2017-2019

    CHOOSE LICENSE TYPE

  • $4850
    $6850
    $8850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Healthcare Clients

Ansell
Styker
Grifols
iqvia
abbvie

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X